Roche/Genentech also revisits data from IMvigor211 atezo vs chemo in mUC by looking at what happends w/ TMB biomarkers and guess what... #GU18
Here we go! $JNJ vs $PFE Ph3 nmCRPC data showdown at #GU18 $JNJ apalutamide Ph3 SPARTAN mPFS 40.5 vs 16.2 mos; HR = 0.28 $PFE Xtandi Ph3 PROSPER mPFS 36.6 vs 14.7 mos; HR = 0.29
Here we go! $JNJ vs $PFE Ph3 nmCRPC data showdown at #GU18 $JNJ apalutamide Ph3 SPARTAN mPFS 40.5 vs 16.2 mos; HR = 0.28 $PFE Xtandi Ph3 PROSPER mPFS 36.6 vs 14.7 mos; HR = 0.29
#GU18 : Genomic alterations (particularly BAP1 or TP53) help refine prognostication in metastatic #RCC. W.Xie
Independent validation! #GU18 “This study confirmed the finding that #HSD3B1 genetic variation is associated with high risk of progression in Japanese men treated with primary ADT for metastatic prostate cancer, suggesting universal significance...”
Active surveillance associated with significantly lower costs for low-risk #prostatecancer compared to radical prostatectomy & radiation therapy -Gaylis et al #GU18 #pcsm
#GU18 : 6-factor prognostic model (ECOG, liver mets, NLR, Hb, Plts, LDH) in #bladder ca Rx w/ post-plat atezolizumab. Pond (),
#GU18 : Impact of tumor size (esp de novo mets) and survival in metastatic #RCC treated with VEGF-TT, via #IMDC. Xie ()
ENZA significantly prolonged median MFS (36.6 mo vs 14.7 mo [P< .0001]) PROSPER: A phase 3, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (M0 CRPC).2018 ASCO
Important news from #ASCOGU2018 #ProstateCancer in patients M0 CRPC PROTECT vs SPARTAN; SPARTAN vs PROTECT ESSENTIAL TO READ BOTH CLINICAL TRIALS
Important news from #ASCOGU2018 #ProstateCancer in patients M0 CRPC PROTECT vs SPARTAN; SPARTAN vs PROTECT ESSENTIAL TO READ BOTH CLINICAL TRIALS
#GU18 $RHHBY Tecentriq Ph3 IMmotion151 data in 1L mRCC PFS HR only 0.74 even in PD-L1 positive population. mPFS the same for PD-L1 positive and negative pts?
#GU18 : Association of low PTEN expression (F-IHC) and lethal disease in men with surgically-treated prostate cancer. et al.
#GU18 #bladder : Correlation of ctDNA and tissue genomics in metastatic #urothelial cancer
#GU18 : Pooled analysis of primary tumor shrinkage in #RCC patients treated with VEGF-TT. McKay et al.
interesting poster session by and others from looking at self reported QOL issues and how they impact survival in #rcc #kidneycancer fyi
and show no correlation between #HSD3B1 variant and abi response - makes sense in light of pharmacogenetic regulation of 5a-Abi generation by #HSD3B1 in Abs 325 #GU18
How does it sounds if your gender determine the aggressiveness of your surgery? #GU18
Excited to present our Trials in Progress Neoadjuvant nivolumab +GC in MIBC #GU18 #bladdercancer
Interesting study about neuropsychiatric adverse events of abiraterone and enzalutamide in mCPRC #GU18
. at 's #GU18 on new research highlighting #testosterone level maintenance throughout #prostatecancer treatment & implications for duration of response to androgen deprivation therapy
Germline #HSD3B1 variant genotype associated with higher 5αA (#androgen receptor agonist) for men with CRPC taking Abi - possible implications for AR stimulation and clinical outcomes. #GU18 #CleClinicCancer
#GU18 $JNJ pan-FGFRi Erdafitinib data in Ph2 bladder cancer with FGFR alterations --> $ARQL 24~35% ORR; 73~74% DCR
#GeriOnc clinics have the potential to avoid overtreatment and improve care for older adults with GU malignancies #GU18
#GeriOnc + #GU18 Major urologic tumor surgery has a high risk of severe complications & incomplete recovery in old pts. Fast & easy-to-do preoperative assessment tools may predict functional outcome more precisely than age or preoperative functional
Shared decision-making for PSA screening performed in <1/3 of patients as of 2012-2016 [email protected] et al #GU18 #prostatecancer #pcsm
Conversation aid tool to enable patients to make an informed decision about whether to proceed/not proceed w adjuvant therapy #GU18 #MedicalDecisionMaking
“QoL was maintained during everolimus therapy and limitations as well as time effort were acceptable for most patients. Everolimus is an effective and safe treatment option following a VEGF(R)-targeted drug.” #GU18
Tomorrow... We will start a #Psychogenomic discussion at #GU18 Association of mutational burden with anxiety and depression.